Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Potent and selective bivalent inhibitors of BET bromodomains.

Waring MJ, Chen H, Rabow AA, Walker G, Bobby R, Boiko S, Bradbury RH, Callis R, Clark E, Dale I, Daniels DL, Dulak A, Flavell L, Holdgate G, Jowitt TA, Kikhney A, McAlister M, Méndez J, Ogg D, Patel J, Petteruti P, Robb GR, Robers MB, Saif S, Stratton N, Svergun DI, Wang W, Whittaker D, Wilson DM, Yao Y.

Nat Chem Biol. 2016 Dec;12(12):1097-1104. doi: 10.1038/nchembio.2210. Epub 2016 Oct 24.

PMID:
27775716
2.

The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.

Oplustil O'Connor L, Rulten SL, Cranston AN, Odedra R, Brown H, Jaspers JE, Jones L, Knights C, Evers B, Ting A, Bradbury RH, Pajic M, Rottenberg S, Jonkers J, Rudge D, Martin NM, Caldecott KW, Lau A, O'Connor MJ.

Cancer Res. 2016 Oct 15;76(20):6084-6094. Epub 2016 Aug 22.

3.

Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).

Bradbury RH, Callis R, Carr GR, Chen H, Clark E, Feron L, Glossop S, Graham MA, Hattersley M, Jones C, Lamont SG, Ouvry G, Patel A, Patel J, Rabow AA, Roberts CA, Stokes S, Stratton N, Walker GE, Ward L, Whalley D, Whittaker D, Wrigley G, Waring MJ.

J Med Chem. 2016 Sep 8;59(17):7801-17. doi: 10.1021/acs.jmedchem.6b00070. Epub 2016 Aug 24.

PMID:
27528113
4.

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.

Weir HM, Bradbury RH, Lawson M, Rabow AA, Buttar D, Callis RJ, Curwen JO, de Almeida C, Ballard P, Hulse M, Donald CS, Feron LJ, Karoutchi G, MacFaul P, Moss T, Norman RA, Pearson SE, Tonge M, Davies G, Walker GE, Wilson Z, Rowlinson R, Powell S, Sadler C, Richmond G, Ladd B, Pazolli E, Mazzola AM, D'Cruz C, De Savi C.

Cancer Res. 2016 Jun 1;76(11):3307-18. doi: 10.1158/0008-5472.CAN-15-2357. Epub 2016 Mar 28.

5.

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.

De Savi C, Bradbury RH, Rabow AA, Norman RA, de Almeida C, Andrews DM, Ballard P, Buttar D, Callis RJ, Currie GS, Curwen JO, Davies CD, Donald CS, Feron LJ, Gingell H, Glossop SC, Hayter BR, Hussain S, Karoutchi G, Lamont SG, MacFaul P, Moss TA, Pearson SE, Tonge M, Walker GE, Weir HM, Wilson Z.

J Med Chem. 2015 Oct 22;58(20):8128-40. doi: 10.1021/acs.jmedchem.5b00984. Epub 2015 Oct 7.

PMID:
26407012
6.

Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.

Finlay MR, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, Bradbury RH, Brown SJ, Butterworth S, Campbell A, Chorley C, Colclough N, Cross DA, Currie GS, Grist M, Hassall L, Hill GB, James D, James M, Kemmitt P, Klinowska T, Lamont G, Lamont SG, Martin N, McFarland HL, Mellor MJ, Orme JP, Perkins D, Perkins P, Richmond G, Smith P, Ward RA, Waring MJ, Whittaker D, Wells S, Wrigley GL.

J Med Chem. 2014 Oct 23;57(20):8249-67. doi: 10.1021/jm500973a. Epub 2014 Oct 1.

PMID:
25271963
7.

Transforming management of tropical coastal seas to cope with challenges of the 21st century.

Sale PF, Agardy T, Ainsworth CH, Feist BE, Bell JD, Christie P, Hoegh-Guldberg O, Mumby PJ, Feary DA, Saunders MI, Daw TM, Foale SJ, Levin PS, Lindeman KC, Lorenzen K, Pomeroy RS, Allison EH, Bradbury RH, Corrin J, Edwards AJ, Obura DO, Sadovy de Mitcheson YJ, Samoilys MA, Sheppard CR.

Mar Pollut Bull. 2014 Aug 15;85(1):8-23. doi: 10.1016/j.marpolbul.2014.06.005. Epub 2014 Jul 2.

8.

Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.

Barlaam B, Anderton J, Ballard P, Bradbury RH, Hennequin LF, Hickinson DM, Kettle JG, Kirk G, Klinowska T, Lambert-van der Brempt C, Trigwell C, Vincent J, Ogilvie D.

ACS Med Chem Lett. 2013 May 31;4(8):742-6. doi: 10.1021/ml400146c. eCollection 2013 Aug 8.

9.

AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo.

Loddick SA, Ross SJ, Thomason AG, Robinson DM, Walker GE, Dunkley TP, Brave SR, Broadbent N, Stratton NC, Trueman D, Mouchet E, Shaheen FS, Jacobs VN, Cumberbatch M, Wilson J, Jones RD, Bradbury RH, Rabow A, Gaughan L, Womack C, Barry ST, Robson CN, Critchlow SE, Wedge SR, Brooks AN.

Mol Cancer Ther. 2013 Sep;12(9):1715-27. doi: 10.1158/1535-7163.MCT-12-1174. Epub 2013 Jul 16.

10.

Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.

Bradbury RH, Acton DG, Broadbent NL, Brooks AN, Carr GR, Hatter G, Hayter BR, Hill KJ, Howe NJ, Jones RD, Jude D, Lamont SG, Loddick SA, McFarland HL, Parveen Z, Rabow AA, Sharma-Singh G, Stratton NC, Thomason AG, Trueman D, Walker GE, Wells SL, Wilson J, Wood JM.

Bioorg Med Chem Lett. 2013 Apr 1;23(7):1945-8. doi: 10.1016/j.bmcl.2013.02.056. Epub 2013 Feb 21.

PMID:
23466225
11.

Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer.

Bradbury RH, Hales NJ, Rabow AA, Walker GE, Acton DG, Andrews DM, Ballard P, Brooks NA, Colclough N, Girdwood A, Hancox UJ, Jones O, Jude D, Loddick SA, Mortlock AA.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5442-5. doi: 10.1016/j.bmcl.2011.06.122. Epub 2011 Jul 2.

PMID:
21782422
12.

Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.

Barlaam B, Acton DG, Ballard P, Bradbury RH, Cross D, Ducray R, Germain H, Hudson K, Klinowska T, Magnien F, Ogilvie DJ, Olivier A, Ross HS, Smith R, Trigwell CB, Vautier M, Wright L.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):1799-803. doi: 10.1016/j.bmcl.2008.02.035. Epub 2008 Feb 16.

PMID:
18313293
13.

Coral reefs under rapid climate change and ocean acidification.

Hoegh-Guldberg O, Mumby PJ, Hooten AJ, Steneck RS, Greenfield P, Gomez E, Harvell CD, Sale PF, Edwards AJ, Caldeira K, Knowlton N, Eakin CM, Iglesias-Prieto R, Muthiga N, Bradbury RH, Dubi A, Hatziolos ME.

Science. 2007 Dec 14;318(5857):1737-42. Review.

PMID:
18079392
14.

A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.

Barlaam B, Ballard P, Bradbury RH, Ducray R, Germain H, Hickinson DM, Hudson K, Kettle JG, Klinowska T, Magnien F, Ogilvie DJ, Olivier A, Pearson SE, Scott JS, Suleman A, Trigwell CB, Vautier M, Whittaker RD, Wood R.

Bioorg Med Chem Lett. 2008 Jan 15;18(2):674-8. Epub 2007 Nov 21.

PMID:
18061446
15.

Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.

Ballard P, Barlaam BC, Bradbury RH, Dishington A, Hennequin LF, Hickinson DM, Hollingsworth IM, Kettle JG, Klinowska T, Ogilvie DJ, Pearson SE, Scott JS, Suleman A, Whittaker R, Williams EJ, Wood R, Wright L.

Bioorg Med Chem Lett. 2007 Nov 15;17(22):6326-9. Epub 2007 Sep 2.

PMID:
17869514
16.

Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.

Ballard P, Bradbury RH, Harris CS, Hennequin LF, Hickinson M, Kettle JG, Kendrew J, Klinowska T, Ogilvie DJ, Pearson SE, Williams EJ, Wilson I.

Bioorg Med Chem Lett. 2006 Sep 15;16(18):4908-12. Epub 2006 Jun 27.

PMID:
16806916
17.

Depletion, degradation, and recovery potential of estuaries and coastal seas.

Lotze HK, Lenihan HS, Bourque BJ, Bradbury RH, Cooke RG, Kay MC, Kidwell SM, Kirby MX, Peterson CH, Jackson JB.

Science. 2006 Jun 23;312(5781):1806-9.

18.

Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket.

Ballard P, Bradbury RH, Harris CS, Hennequin LF, Hickinson M, Johnson PD, Kettle JG, Klinowska T, Leach AG, Morgentin R, Pass M, Ogilvie DJ, Olivier A, Warin N, Williams EJ.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1633-7. Epub 2005 Dec 27.

PMID:
16380259
19.

5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase.

Ballard P, Bradbury RH, Hennequin LF, Hickinson DM, Johnson PD, Kettle JG, Klinowska T, Morgentin R, Ogilvie DJ, Olivier A.

Bioorg Med Chem Lett. 2005 Oct 1;15(19):4226-9.

PMID:
16055332
20.

Ecology. Are U.S. coral reefs on the slippery slope to slime?

Pandolfi JM, Jackson JB, Baron N, Bradbury RH, Guzman HM, Hughes TP, Kappel CV, Micheli F, Ogden JC, Possingham HP, Sala E.

Science. 2005 Mar 18;307(5716):1725-6. No abstract available. Erratum in: Science. 2005 Jun 17;308(5729):1742-3.

PMID:
15774744
21.

Global trajectories of the long-term decline of coral reef ecosystems.

Pandolfi JM, Bradbury RH, Sala E, Hughes TP, Bjorndal KA, Cooke RG, McArdle D, McClenachan L, Newman MJ, Paredes G, Warner RR, Jackson JB.

Science. 2003 Aug 15;301(5635):955-8.

22.

Historical overfishing and the recent collapse of coastal ecosystems.

Jackson JB, Kirby MX, Berger WH, Bjorndal KA, Botsford LW, Bourque BJ, Bradbury RH, Cooke R, Erlandson J, Estes JA, Hughes TP, Kidwell S, Lange CB, Lenihan HS, Pandolfi JM, Peterson CH, Steneck RS, Tegner MJ, Warner RR.

Science. 2001 Jul 27;293(5530):629-37. Review.

PMID:
11474098
23.

New non-peptide endothelin-A receptor antagonists: synthesis, biological properties, and structure-activity relationships of 5-(dimethylamino)-N-pyridyl-,-N-pyrimidinyl-,-N-pyridazinyl-, and -N-pyrazinyl-1-naphthalenesulfonamides.

Bradbury RH, Bath C, Butlin RJ, Dennis M, Heys C, Hunt SJ, James R, Mortlock AA, Sumner NF, Tang EK, Telford B, Whiting E, Wilson C.

J Med Chem. 1997 Mar 14;40(6):996-1004.

PMID:
9083490
24.

New nonpeptide angiotensin II receptor antagonists. 3. Synthesis, biological properties, and structure-activity relationships of 2-alkyl-4-(biphenylylmethoxy)pyridine derivatives.

Bradbury RH, Allott CP, Dennis M, Girdwood JA, Kenny PW, Major JS, Oldham AA, Ratcliffe AH, Rivett JE, Roberts DA, et al.

J Med Chem. 1993 Apr 30;36(9):1245-54.

PMID:
8487261
25.

New nonpeptide angiotensin II receptor antagonists. 2. Synthesis, biological properties, and structure-activity relationships of 2-alkyl-4-(biphenylylmethoxy)quinoline derivatives.

Bradbury RH, Allott CP, Dennis M, Fisher E, Major JS, Masek BB, Oldham AA, Pearce RJ, Rankine N, Revill JM, et al.

J Med Chem. 1992 Oct 30;35(22):4027-38.

PMID:
1433210
27.

1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity. 2. Synthesis, biological properties and molecular modeling of hydroxyethylene isostere derivatives.

Bradbury RH, Major JS, Oldham AA, Rivett JE, Roberts DA, Slater AM, Timms D, Waterson D.

J Med Chem. 1990 Sep;33(9):2335-42.

PMID:
2118184
28.

1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity. 1. Synthesis and biological properties of alkyl alcohol and statine derivatives.

Roberts DA, Bradbury RH, Brown D, Faull A, Griffiths D, Major JS, Oldham AA, Pearce RJ, Ratcliffe AH, Revill J, et al.

J Med Chem. 1990 Sep;33(9):2326-34.

PMID:
2118183
29.

Atypical Johne's disease in a cow.

BRADBURY RH.

North Am Vet. 1950 Jun;31(6):393-4. No abstract available.

PMID:
15417016
30.

Observations on canine leucemia.

BRADBURY RH.

Vet Med. 1949 Mar;44(3):116. No abstract available.

PMID:
18114818
31.

Bovine sterility; case history.

BRADBURY RH.

North Am Vet. 1948 Dec;29(12):773-7. No abstract available.

PMID:
18895295
32.

Sulfa reaction or lead poisoning.

BRADBURY RH.

North Am Vet. 1948 Aug;29(8):489-91. No abstract available.

PMID:
18874918
33.

Clinical application of mine detector.

BRADBURY RH.

North Am Vet. 1947 Oct;28(10):661-3. No abstract available.

PMID:
20264441

Supplemental Content

Loading ...
Support Center